HRP20150082T1 - Derivati pirazolo piridina kao inhibitori nadph oksidaze - Google Patents

Derivati pirazolo piridina kao inhibitori nadph oksidaze Download PDF

Info

Publication number
HRP20150082T1
HRP20150082T1 HRP20150082AT HRP20150082T HRP20150082T1 HR P20150082 T1 HRP20150082 T1 HR P20150082T1 HR P20150082A T HRP20150082A T HR P20150082AT HR P20150082 T HRP20150082 T HR P20150082T HR P20150082 T1 HRP20150082 T1 HR P20150082T1
Authority
HR
Croatia
Prior art keywords
optionally substituted
group
pyrazolo
methyl
pyridine
Prior art date
Application number
HRP20150082AT
Other languages
English (en)
Inventor
Patrick Page
Mike Orchard
Benoît Laleu
Francesca Gaggini
Original Assignee
Genkyotex Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genkyotex Sa filed Critical Genkyotex Sa
Publication of HRP20150082T1 publication Critical patent/HRP20150082T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Ophthalmology & Optometry (AREA)

Claims (16)

1. Derivat pirazolo piridina opće formule(I): [image] naznačen time, da je G1 odabran iz grupe koju čine H; opcionalno supstituirana acil grupa; opcionalno supstituirana acil C1-C6 alkil grupa; opcionalno supstituirana alkil C3-C8-cikloalkil alkil grupa; opcionalno supstituirana heterocikloalkil alkil grupa; opcionalno supstituirana aril alkil grupa; i opcionalno supstituirana heteroaril alkil grupa; G2 je odabran iz grupe koju čine H; opcionalno supstituirana C1-C6 alkil grupa; opcionalno supstituirana C2-C6 alkenil grupa; opcionalno supstituirana C2-C6 alkinil grupa; opcionalno supstituirana aril grupa; opcionalno supstituirana C1-C6 alkil aril grupa; opcionalno supstituirana aril C1-C6 alkil grupa; opcionalno supstituirana heteroaril grupa; opcionalno supstituirana alkil heteroaril grupa; opcionalno supstituirana heteroaril C1-C6 alkil grupa; opcionalno supstituirana C2-C6 alkenil aril grupa; opcionalno supstituirana aril C2-C6 alkenil grupa; opcionalno supstituirana C2-C6 alkenil heteroaril grupa; opcionalno supstituirana heteroaril C2-C6 alkenil grupa; opcionalno supstituirana C3-C8-cikloalkil grupa; opcionalno supstituirana heterocikloalkil grupa; opcionalno supstituirana alkil C3-C8-cikloalkil grupa; opcionalno supstituirana C3-C8-cikloalkil C1-C6 alkil grupa; opcionalno supstituirana C1-C6 alkil heterocikloalkil grupa i opcionalno supstituirana heterocikloalkil C1-C6 alkil grupa; G3 je odabran iz grupe koju čine H; opcionalno supstituirana amino grupa; opcionalno supstituirana aminoalkil grupa; opcionalno supstituirana aminokarbonil grupa; opcionalno supstituirana alkoksi grupa; opcionalno supstituirana alkoksi C1-C6 alkil grupa; opcionalno supstituirana karbonil grupa; opcionalno supstituirana C1-C6 alkil grupa; opcionalno supstituirana C2-C6 alkenil grupa; opcionalno supstituirana C2-C6 alkinil grupa; opcionalno supstituirana aril grupa; opcionalno supstituirana aril C1-C6 alkil grupa; opcionalno supstituirana heteroaril grupa; opcionalno supstituirana C1-C6 alkil heteroaril grupa; opcionalno supstituirana heteroaril C1-C6 alkil grupa; opcionalno supstituirana C2-C6 alkenil aril grupa; opcionalno supstituirana aril C2-C6 alkenil grupa; opcionalno supstituirana C2-C6 alkenil heteroaril grupa; opcionalno supstituirana heteroaril C2-C6 alkenil grupa; opcionalno supstituirana C3-C8-cikloalkil grupa; opcionalno supstituirana heterocikloalkil grupa; opcionalno supstituirana C1-C6 alkil C3-C8-cikloalkil grupa; opcionalno supstituirana C3-C8-cikloalkil C1-C6 alkil grupa; opcionalno supstituirana C1-C6 alkil heterocikloalkil grupa i opcionalno supstituirana heterocikloalkil C1-C6 alkil grupa; G4 je odabran između -NR2-C(O)-R1 i -(CHR3)m-(CH2)n-R4 grupe, gdje je R1 odabran iz grupe koju čine H; amino grupa; -NR5R6; opcionalno supstituirana alkoksi grupa; opcionalno supstituirana alkoksi C1-C6 alkil grupa; opcionalno supstituirana aril grupa; opcionalno supstituirana C1-C6 alkil aril grupa; opcionalno supstituirana aril C1-C6 alkil grupa; heteroaril grupa; opcionalno supstituirana C1-C6 alkil heteroaril grupa; opcionalno supstituirana heteroaril C1-C6 alkil grupa; opcionalno supstituirana C3-C8-cikloalkil grupa; opcionalno supstituirana C1-C6 alkil C3-C8-cikloalkil grupa; opcionalno supstituirana C3-C8-cikloalkil C1-C6 alkil grupa; opcionalno supstituirana heterocikloalkil grupa; opcionalno supstituirana C1-C6 alkil heterocikloalkil grupa; i opcionalno supstituirana heterocikloalkil C1-C6 alkil grupa; R2 je odabran iz grupe koju čine H grupa; opcionalno supstituirana alkoksi C1-C6 alkil grupa; opcionalno supstituirana aril grupa; opcionalno supstituirana C1-C6 alkil aril grupa; opcionalno supstituirana aril C1-C6 alkil grupa; opcionalno supstituirana heteroaril grupa; opcionalno supstituirana C1-C6 alkil heteroaril grupa; opcionalno supstituirana heteroaril C1-C6 alkil grupa; opcionalno supstituirana C3-C8-cikloalkil grupa; opcionalno supstituirana C1-C6 alkil C3-C8-cikloalkil grupa; opcionalno supstituirana C3-C8-cikloalkil C1-C6 alkil grupa; opcionalno supstituirana heterocikloalkil grupa; opcionalno supstituirana C1-C6 alkil heterocikloalkil grupa; opcionalno supstituirana heterocikloalkil C1-C6 alkil grupa; R3 je odabran iz grupe koju čine H; halogena grupa; opcionalno supstituirana alkoksi grupa; opcionalno supstituirana alkoksi C1-C6 alkil aril grupa; opcionalno supstituirana C1-C6 alkil aril grupa; opcionalno supstituirana aril C1-C6 alkil grupa; opcionalno supstituirana heteroaril grupa; opcionalno supstituirana C1-C6 alkil heteroaril grupa; opcionalno supstituirana heteroaril C1-C6 alkil grupa; opcionalno supstituirana C3-C8-cikloalkil grupa; opcionalno supstituirana C1-C6 alkil C3-C8-cikloalkil grupa; opcionalno supstituirana C3-C8-cikloalkil C1-C6 alkil grupa; heterocikloalkil grupa; opcionalno supstituirana C1-C6 alkil heterocikloalkil grupa; i opcionalno supstituirana heterocikloalkil C1-C6 alkil grupa; R4 je odabran iz grupe koju čine H; -C(O)R7grupa; -A-B grupa; -CHR8R9 i -(CH2)q-E grupa; R5 i R6 su neovisno odabrani iz grupe koju čine H; opcionalno supstituirana alkoksi C1-C6 alkil grupa; opcionalno supstituirana aril grupa; opcionalno supstituirana C1-C6 alkil aril grupa; opcionalno supstituirana aril C1-C6 alkil grupa; opcionalno supstituirana heteroaril grupa; opcionalno supstituirana C1-C6 alkil heteroaril grupa; opcionalno supstituirana heteroaril C1-C6 alkil grupa; opcionalno supstituirana C3-C8-cikloalkil grupa; opcionalno supstituirana C1-C6 alkil C3-C8-cikloalkil grupa; opcionalno supstituirana C3-C8-cikloalkil C1-C6 alkil grupa; opcionalno supstituirana heterocikloalkil grupa; opcionalno supstituirana C1-C6 alkil heterocikloalkil grupa; i opcionalno supstituirana heterocikloalkil C1-C6 alkil grupa ili -NR5R6 čine zajedno prsten odabran od opcionalno supstituiranog heteroarilnog ili opcionalno supstituiranog heterocikloalkilnog prstena; R7 je odabran iz grupe koju čine opcionalno supstituirana amino grupa; opcionalno supstituirana alkoksi grupa; opcionalno supstituirana aminoalkil grupa; opcionalno supstituirana alkoksi C1-C6 alkil grupa; opcionalno supstituirana C1-C6 alkil grupa; opcionalno supstituirana C2-C6 alkenil grupa; opcionalno supstituirana C2-C6 alkinil grupa; -NR5R6; opcionalno supstituirana aril grupa; opcionalno supstituirana C1-C6 alkil aril grupa; opcionalno supstituirana aril C1-C6 alkil grupa; opcionalno supstituirana heteroaril grupa; opcionalno supstituirana C1-C6 alkil heteroaril grupa; opcionalno supstituirana heteroaril C1-C6 alkil grupa; opcionalno supstituirana C3-C8-cikloalkil grupa; opcionalno supstituirana C1-C6 alkil C3-C8-cikloalkil grupa; opcionalno supstituirana C3-C8-cikloalkil C1-C6 alkil grupa; opcionalno supstituirana heterocikloalkil grupa; opcionalno supstituirana C1-C6 alkil heterocikloalkil grupa; i opcionalno supstituirana heterocikloalkil C1-C6 alkil grupa; R8 i R9 su neovisno odabrani iz grupe koju čine opcionalno supstituirana aril grupa; opcionalno supstituirana heteroaril grupa; opcionalno supstituirana C3-C8-cikloalkil grupa i opcionalno supstituirana heterocikloalkil grupa; R10 je odabran između opcionalno supstituirane aril grupe i opcionalno supstituirane heteroaril grupe; R11 i R12 su neovisno odabrani iz grupe koju čine H; opcionalno supstituirana acil grupa; opcionalno supstituirana C1-C6 alkil grupa; opcionalno supstituirana C2-C6 alkenil grupa; opcionalno supstituirana C2-C6 alkinil grupa; opcionalno supstituirana aril grupa; opcionalno supstituirana C1-C6 alkil aril grupa; opcionalno supstituirana aril C1-C6 alkil grupa; opcionalno supstituirana heteroaril grupa; opcionalno supstituirana C1-C6 alkil heteroaril grupa; opcionalno supstituirana heteroaril C1-C6 alkil grupa; opcionalno supstituirana C3-C8-cikloalkil grupa; opcionalno supstituirana C1-C6 alkil C3-C8-cikloalkil grupa; opcionalno supstituirana C3-C8-cikloalkil C1-C6 alkil grupa; opcionalno supstituirana heterocikloalkil grupa; opcionalno supstituirana C1-C6 alkil heterocikloalkil grupa; i opcionalno supstituirana heterocikloalkil C1-C6 alkil grupa ili -NR11R12 čine zajedno prsten odabran od opcionalno supstituiranog heteroarilnog ili opcionalno supstituiranog heterocikloalkilnog prstena; R13 je odabran iz grupe koju čine opcionalno supstituirana aril grupa; opcionalno supstituirana heteroaril grupa; opcionalno supstituirana C3-C8-cikloalkil grupa i opcionalno supstituirana heterocikloalkil grupa; R14, R15 i R16 su neovisno odabrani između H i opcionalno supstituirane C1-C6 alkil grupe; R17 je odabran iz grupe koju čine opcionalno supstituirana C1-C6 alkil grupa; opcionalno supstituirana C2-C6 alkenil grupa; opcionalno supstituirana C2-C6 alkinil grupa; aril grupa; opcionalno supstituirana C1-C6 alkil aril grupa; opcionalno supstituirana aril C1-C6 alkil grupa; opcionalno supstituirana heteroaril grupa; opcionalno supstituirana C1-C6 alkil heteroaril grupa; opcionalno supstituirana heteroaril C1-C6 alkil grupa; opcionalno supstituirana C3-C8-cikloalkil grupa; opcionalno supstituirana C1-C6 alkil C3-C8-cikloalkil grupa; opcionalno supstituirana C3-C8-cikloalkil C1-C6 alkil grupa; opcionalno supstituirana heterocikloalkil grupa; opcionalno supstituirana C1-C6 alkil heterocikloalkil grupa; i opcionalno supstituirana heterocikloalkil C1-C6 alkil grupa; A je odabran između opcionalno supstituirane aril i opcionalno supstituirane heteroaril grupe; B je odabran između -OR10, -NR11R12 i -(CH2)p-R13grupe; E je odabran iz grupe koju čine opcionalno supstituirana C3-C8-cikloalkil grupa; opcionalno supstituirana C2-C6 alkinil grupa; -NR14R15-(CH2)r-OR15 i NR16C(O)-R17 grupa; m, n, p i q označavaju cijele brojeve od 0 do 5; r označava cijeli broj od 3 do 5; G5 je odabran iz grupe koju čine H; opcionalno supstituirana C1-C6 alkil grupa; opcionalno supstituirana C2-C6 alkenil grupa; opcionalno supstituirana C2-C6 alkinil grupa; opcionalno supstituirana aril grupa; opcionalno supstituirana C1-C6 alkil aril grupa; opcionalno supstituirana aril C1-C6 alkil grupa; opcionalno supstituirana heteroaril grupa; opcionalno supstituirana C1-C6 alkil heteroaril grupa; opcionalno supstituirana heteroaril C1-C6 alkil grupa; opcionalno supstituirana C2-C6 alkenil aril grupa; opcionalno supstituirana aril C2-C6 alkenil grupa; opcionalno supstituirana C2-C6 alkenil heteroaril grupa; opcionalno supstituirana heteroaril C2-C6 alkenil grupa; opcionalno supstituirana C3-C8-cikloalkil grupa; opcionalno supstituirana heterocikloalkil grupa; opcionalno supstituirana C1-C6 alkil C3-C8-cikloalkil grupa; opcionalno supstituirana C3-C8-cikloalkil C1-C6 alkil grupa; opcionalno supstituirana C1-C6 alkil heterocikloalkil grupa i opcionalno supstituirana heterocikloalkil C1-C6 alkil grupa; kao i njihove farmaceutski prihvatljive soli.
2. Derivat prema patentnom zahtjevu 1, naznačen time da G1 je H.
3. Derivat prema patentnim zahtjevima 1 ili 2, naznačen time da G3 je C1-C6 alkil grupa.
4. Derivat prema patentnim zahtjevima 1 ili 2, naznačen time da G3 je amino grupa.
5. Derivat prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time da je G4 -NR2-C(O)-R1 grupa; a R1 i R2 su kao što je to definirano u bilo kojem od prethodnih patentnih zahtjeva.
6. Derivat prema bilo kojem od patentnih zahtjeva od 1 do 4, naznačen time da je G4 -(CHR3)m-(CH2)n-R4 grupa; R3, R4, m i n su kao što je to definirano u bilo kojem od prethodnih patentnih zahtjeva.
7. Derivat prema patentnim zahtjevima 1 ili 6, naznačen time da je R4-C(O)R7 grupa; R7 je kao što je to definirano u bilo kojem od prethodnih patentnih zahtjeva.
8. Derivat prema patentnim zahtjevima 1 ili 6, naznačen time da je R4 -A-B; A i B su kao što je to definirano u bilo kojem od prethodnih patentnih zahtjeva.
9. Derivat prema patentnim zahtjevima 1 ili 6, naznačen time da je R4 -CHR8R9; R8 i R9 su kao što je to definirano u bilo kojem od prethodnih patentnih zahtjeva.
10. Derivat prema patentnim zahtjevima 1 ili 6, naznačen time da je R4 -(CH2)q-E; E i q su kao što je to definirano u bilo kojem od prethodnih patentnih zahtjeva.
11. Derivat prema bilo kom od prethodnih patentnih zahtjeva, naznačen time da G5 je H.
12. Derivat prema bilo kojem od patentnih zahtjeva od 1 do 11, odabran iz grupe koju čine: 2-((2-klorofenil)-4-metil-5-(2-morfolin-4-ilbenzil)-1H-pirazolo[4,3-c]piridin-3,6(2H,5H)-dion; 2-((2-klorofenil)-4-metil-5-{4-[(4-metilpiperazin-1-il)metil]benzil}-1H-pirazolo[4,3-c]piridin-3,6(2H,5H)-dion; 2-((2-klorofenil)-4-metil-5-(2-morfolin-4-il-2-feniletil)-1H-pirazolo[4,3-c]piridin-3,6(2H,5H)-dion; 2-((2-klorofenil)-5-[2-(4-hidroksifenil)etil]-4-metil-1H-pirazolo[4,3-c]piridin-3,6(2H,5H)-dion; 5-((3-etoksipropil)-4-metil-2-(4-fenil-1,3-tiazol-2-il)-1H-pirazolo[4,3-c]piridin-3,6(2H,5H)-dion; 2-((2-klorofenil)-4,5-dimetil-1H-pirazolo[4,3-c]piridin-3,6(2H,5H)-dion; 2-((2-fluorofenil)-4,5-dimetil-1H-pirazolo[4,3-c]piridin-3,6(2H,5H)-dion; 4-metil-5-(3-fenoksibenzil)-2-(4-fenil-1,3-tiazol-2-il)-1H-pirazolo[4,3-c]piridin-3,6(2H,5H)-dion; 4,5-dimetil-2-(4-fenil-1,3-tiazol-2-il)-1H-pirazolo[4,3-c]piridin-3,6(2H,5H)-dion; 2-((3-klorofenil)-4,5-dimetil-1H-pirazolo[4,3-c]piridin-3,6(2H,5H)-dion; N-[2-(2-klorofenil)-4-metil-3,6-diokso-1,2,3,6-tetrahidro-5H-pirazolo[4,3-c]piridin-5-il]-2-(4-fluorofenoksi)acetamid; 2-((2-klorofenil)-4-metil-5-(3-fenoksibenzil)-1H-pirazolo[4,3-c]piridin-3,6(2H,5H)-dion; 5-((3-etoksipropil)-2-(2-fluorofenil)-4-metil-1H-pirazolo[4,3-c]piridin-3,6(2H,5H)-dion; 2-((3-klorofenil)-5-(3-etoksipropil)-4-metil-1H-pirazolo[4,3-c]piridin-3,6(2H,5H)-dion; 2-((3-klorofenil)-4-metil-5-[2-(morfolin-4-ilmetil)benzil]-1H-pirazolo[4,3-c]piridin-3,6(2H,5H)-dion; 2-((2-fluorofenil)-4-metil-5-[2-(morfolin-4-ilmetil)benzil]-1H-pirazolo[4,3-c]piridin-3,6(2H,5H)-dion; 2-((2-fluorofenil)-4-metil-5-[(6-morfolin-4-ilpiridin-2-il)metil]-1H-pirazolo[4,3-c]piridin-3,6(2H,5H)-dion; 2-((2-fluorofenil)-4-metil-5-[4-(morfolin-4-ilmetil)benzil]-1H-pirazolo[4,3-c]piridin-3,6(2H,5H)-dion; 2-((3-klorofenil)-4-metil-5-[(6-morfolin-4-ilpiridin-2-il)metil]-1H-pirazolo[4,3-c]piridin-3,6(2H,5H)-dion; 3-((4,5-dimetil-3,6-diokso-1,3,5,6-tetrahidro-2H-pirazolo[4,3-c]piridin-2-il)benzonitril; 2-((2-fluorofenil)-4-metil-5-(3-fenoksibenzil)-1H-pirazolo[4,3-c]piridin-3,6(2H,5H)-dion; 2-((3-klorofenil)-4-metil-5-(3-fenoksibenzil)-1H-pirazolo[43-c]piridin-3,6(2H,5H)-dion; 2-((2-klorofenil)-5-(3-etoksipropil)-4-metil-1H-pirazolo[4,3-c]piridin-3,6(2H,5H)-dion; 2-((2-klorofenil)-4-metil-5-[(6-morfolin-4-ilpiridin-2-il)metil]-1H-pirazolo[4,3-c]piridin-3,6(2H,5H)-dion; 2-((3-klorofenil)-4-metil-5-[4-(4-metilpiperazin-1-il)-4-oksobutil]-1H-pirazolo[4,3-c]piridin-3,6(2H,5H)-dion; 2-((3-klorofenil)-4-metil-5-[4-(morfolin-4-ilmetil)benzil]-1H-pirazolo[4,3-c]piridin-3,6(2H,5H)-dion; 2-[2-(2-fluorofenil)-4-metil-3,6-diokso-1,2,3,6-tetrahidro-5H-pirazolo[4,3-c]piridin-5-il]-N-(piridin-2-ilmetil)acetamid; 2-((2-klorofenil)-4-metil-5-[4-(morfolin-4-ilmetil)benzil]-1H-pirazolo[4,3-c]piridin-3,6(2H,5H)-dion; 2-((2-klorofenil)-4-metil-5-[2-(morfolin-4-ilmetil)benzil]-1H-pirazolo[4,3-c]piridin-3,6(2H,5H)-dion; 4-metil-5-(3-fenoksibenzil)-2-[1,2,4]triazolo[4,3-b]piridazin-6-il-1H-pirazolo[4,3-c]piridin-3,6(2H,5H)-dion; 3-[5-(3-etoksipropil)-4-metil-3,6-diokso-1,3,5,6-tetrahidro-2H-pirazolo[4,3-c]piridin-2-il]benzonitril; 2-[4-(benziloksi)fenil]-4,5-dimetil-1H-pirazolo[4,3-c]piridin-3,6(2H,5H)-dion; 2-[4-(benziloksi)fenil]-4-metil-5-(3-fenoksibenzil)-1H-pirazolo[4,3-c]piridin-3,6(2H,5H)-dion; 2-[4-(benziloksi)fenil]-5-(3-etoksipropil)-4-metil-1H-pirazolo[4,3-c]piridin-3,6(2H,5H)-dion; 3-{4-metil-5-[4-(morfolin-4-ilmetil)benzil]-3,6-diokso-1,3,5,6-tetrahidro-2H-pirazolo[4,3-c]piridin-2-il}benzonitril; 2-((2-klorofenil)-5-(3-hidroksipropil)-4-metil-1H-pirazolo[4,3-c]piridin-3,6(2H,5H)-dion; 2-[2-(2-klorofenil)-4-metil-3,6-diokso-1,2,3,6-tetrahidro-5H-pirazolo[4,3-c]piridin-5-il]-N-(piridin-2-ilmetil)acetamid; 2-[2-(3-cijanofenil)-4-metil-3,6-diokso-1,2,3,6-tetrahidro-5H-pirazolo[4,3-c]piridin-5-il]-N-(piridin-2-ilmetil)acetamid; 2-[2-(3-klorofenil)-4-metil-3,6-diokso-1,2,3,6-tetrahidro-5H-pirazolo[4,3-c]piridin-5-il]-N-(piridin-2-ilmetil)acetamid; 2-((2-klorofenil)-5-(3-etoksipropil)-4-metil-1-(piridin-2-ilmetil)-1H-pirazolo[4,3-c]piridin-3,6(2H,5H)-dion; 2,4-dimetil-5-(3-fenoksibenzil)-1H-pirazolo[4,3-c]piridin-3,6(2H,5H)-dion; 2-((2-klorofenil)-5-[3-(dietilamino)propil]-4-metil-1H-pirazolo[4,3-c]piridin-3,6(2H,5H)-dion; 2-((2-klorofenil)-5-(cikloheksilmetil)-4-metil-1H-pirazolo[4,3-c]piridin-3,6(2H,5H)-dion; 2-((3-klorofenil)-5-(3-hidroksipropil)-4-metil-1H-pirazolo[4,3-c]piridin-3,6(2H,5H)-dion; 2-((2-klorofenil)-4-metil-5-[4-(4-metilpiperazin-1-il)-4-oksobutil]-1H-pirazolo[4,3-c]piridin-3,6(2H,5H)-dion; 2-((2-klorofenil)-5-(3-fenoksibenzil)-1H-pirazolo[4,3-c]piridin-3,6(2H,5H)-dion; 2-((3-klorofenil)-4-metil-5-(3-morfolin-4-il-3-fenilpropil)-1H-pirazolo[4,3-c]piridin-3,6(2H,5H)-dion; 2-((3-klorofenil)-4-metil-5-(3-fenilprop-2-in-1-il)-1H-pirazolo[4,3-c]piridin-3,6(2H,5H)-dion; 2-((2-kloro-4-fluorofenil)-4-metil-5-[2-(morfolin-4-ilmetil)benzil]-1H-pirazolo[4,3-c]piridin-3,6(2H,5H)-dion; 4,5-dimetil-2-{5-[(4-metilpiperazin-1-il)sulfonil]piridin-2-il}-1H-pirazolo[4,3-c]piridin-3,6(2H,5H)-dion; 2-((2-fluorofenil)-4-metil-5-(3-morfolin-4-il-3-fenilpropil)-1H-pirazolo[4,3-c]piridin-3,6(2H,5H)-dion; 2-((2,5-diklorofenil)-4-metil-5-[2-(morfolin-4-ilmetil)benzil]-1H-pirazolo[4,3-c]piridin-3,6(2H,5H)-dion; 2-[2-(benziloksi)fenil]-5-(3-etoksipropil)-4-metil-1H-pirazolo[4,3-c]piridin-3,6(2H,5H)-dion; 2-((2,5-diklorofenil)-4-metil-5-(2-morfolin-4-il-2-oksoetil)-1H-pirazolo[4,3-c]piridin-3,6(2H,5H)-dion; N-{2-[2-(2,5-diklorofenil)-4-metil-3,6-diokso-1,2,3,6-tetrahidro-5H-pirazolo[4,3-c]piridin-5-il]etil}acetamid; 2-((2-kloro-4-fluorofenil)-4-(metoksimeti)-5-[2-(morfolin-4-ilmetil)benzil]-1H-pirazolo[4,3-c]piridin-3,6(2H,5H)-dion; 2-((2-klorofenil)-5-[2-(dimetilamino)etil]-4-metil-1H-pirazolo[4,3-c]piridin-3,6(2H,5H)-dion; 2-[4-(benziloksi)fenil]-4-metil-5-[2-(morfolin-4-ilmetil)benzil]-1H-pirazolo[4,3-c]piridin-3,6(2H,5H)-dion; 2-((3-klorofenil)-4-metil-5-[2-(4-metilpiperazin-1-il)benzil]-1H-pirazolo[4,3-c]piridin-3,6(2H,5H)-dion; 2-((3,4-diklorofenil)-4-metil-5-[4-(4-metilpiperazin-1-il)-4-oksobutil]-1H-pirazolo[4,3-c]piridin-3,6(2H,5H)-dion; 5-[2-(4-benzilpiperazin-1-il)-2-oksoetil]-2-(2,5-diklorofenil)-4-metil-1H-pirazolo[4,3-c]piridin-3,6(2H,5H)-dion; 2-((2-klorofenil)-4-metil-5-(3-fenilprop-2-in-1-il)-1H-pirazolo[4,3-c]piridin-3,6(2H,5H)-dion; N-{3-[5-(3-etoksipropil)-4-metil-3,6-diokso-1,3,5,6-tetrahidro-2H-pirazolo[4,3-c]piridin-2-il]fenil}acetamid; 2-benzil-4-metil-5-[2-(morfolin-4-ilmetil)benzil]-1H-pirazolo[4,3-c]piridin-3,6(2H,5H)-dion; 2-((3,4-diklorofenil)-4-metil-5-[2-(morfolin-4-ilmetil)benzil]-1H-pirazolo[4,3-c]piridin-3,6(2H,5H)-dion; 2-((2-kloro-4-fluorofenil)-4,5-dimetil-1H-pirazolo[4,3-c]piridin-3,6(2H,5H)-dion; 2-[4-(benziloksi)fenil]-4-metil-5-(2-morfolin-4-il-2-oksoetil)-1H-pirazolo[4,3-c]piridin-3,6(2H,5H)-dion; 2-((3,4-diklorfenil)-4-metil-5-(2-morfolin-4-il-2-oksoetil)-1H-pirazolo[4,3-c]piridin-3,6(2H,5H)-dion; metil[2-(2,5-diklorofenil)-4-metil-3,6-diokso-1,2,3,6-tetrahidro-5H-pirazolo[4,3-c]piridin-5-il]acetat; N-{3-[2-(2,3-diklorofenil)-4-metil-3,6-diokso-1,2,3,6-tetrahidro-5H-pirazolo[4,3-c]piridin-5-il]fenil}acetamid; 2-((2,3-diklorofenil)-4-metil-5-[4-(4-metilpiperazin-1-il)-4-oksobutil]-1H-pirazolo[4,3-c]piridin-3,6(2H,5H)-dion; N-{3-[2-(3-kloro-4-fluorofenil)-4-metil-3,6-diokso-1,2,3,6-tetrahidro-5H-pirazolo[4,3-c]piridin-5-il]fenil}acetamid; 5-[2-(4-benzilpiperazin-1-il)-2-oksoetil]-2-(3,4-diklorofenil)-4-metil-1H-pirazolo[4,3-c]piridin-3,6(2H,5H)-dion; 2,4-dimetil-5-[2-(morfolin-4-ilmetil)benzil]-1H-pirazolo[4,3-c]piridin-3,6(2H,5H)-dion; 2,4-dimetil-5-(3-morfolin-4-il-3-fenilpropil)-1H-pirazolo[4,3-c]piridin-3,6(2H,5H)-dion; N-{3-[2-(2-kloro-4-fluorofenil)-4-metil-3,6-diokso-1,2,3,6-tetrahidro-5H-pirazolo[4,3-c]piridin-5-il]fenil}acetamid; 2-((3-klorofenil)-5-(3-etoksipropil)-4-(3-metoksibenzil)-1H-pirazolo[4,3-c]piridin-3,6(2H,5H)-dion; 2-((2,4-dimetil-3,6-diokso-1,2,3,6-tetrahidro-5H-pirazolo[4,3-c]piridin-5-il)-N-(piridin-2-ilmetil)acetamid; 2-((3-kloro-4-fluorofenil)-4-metil-5-(2-morfolin-4-il-2-oksoetil)-1H-pirazolo[4,3-c]piridin-3,6(2H,5H)-dion; 2-((3-kloro-4-fluorofenil)-4-metil-5-[4-(4-metilpiperazin-1-il)-4-oksobutil]-1H-pirazolo[4,3-c]piridin-3,6(2H,5H)-dion; 2-((2-kloro-4-fluorofenil)-4-metil-5-(2-morfolin-4-il-2-oksoetil)-1H-pirazolo[4,3-c]piridin-3,6(2H,5H)-dion; 5-[2-(4-benzilpiperazin-1-il)-2-oksoetil]-2-(2-kloro-4-fluorofenil)-4-metil-1H-pirazolo[4,3-c]piridin-3,6(2H,5H)-dion; 2-[4-(benziloksi)fenil]-4-metil-5-[4-(4-metilpiperazin-1-il)-4-oksobutil]-1H-pirazolo[4,3-c]piridin-3,6(2H,5H)-dion; 2-((2,3-diklorfenil)-4-metil-5-[2-(morfolin-4-ilmetil)benzil]-1H-pirazolo[4,3-c]piridin-3,6(2H,5H)-dion; 2-((2-kloro-4-fluorofenil)-4-metil-5-[2-(4-metilpiperazin-1-il)benzil]-1H-pirazolo[4,3-c]piridin-3,6(2H,5H)-dion; N-(3-{[2-(3-kloro-4-fluorofenil)-4-metil-3,6-diokso-1,2,3,6-tetrahidro-5H-pirazolo[4,3-c]piridin-5-il]metil}fenil)acetamid; 5-[2-(4-benzilpiperazin-1-il)-2-oksoetil]-2-(3-kloro-4-fluorofenil)-4-metil-1H-pirazolo[4,3-c]piridin-3,6(2H,5H)-dion; N-(3-{[2-(2-kloro-4-fluorofenil)-4-metil-3,6-diokso-1,2,3,6-tetrahidro-5H-pirazolo[4,3-c]piridin-5-il]metil}fenil)acetamid; 2-((2-kloro-4-fluorofenil)-4-metil-5-[4-(4-metilpiperazin-1-il)-4-oksobutil]-1H-pirazolo[4,3-c]piridin-3,6(2H,5H)-dion; 3-{4-metil-5-[2-(morfolin-4-ilmetil)benzil]-3,6-diokso-1,3,5,6-tetrahidro-2H-pirazolo[4,3-c]piridin-2-il}benzonitril; N-{2-[2-(3-kloro-4-fluorofenil)-4-metil-3,6-diokso-1,2,3,6-tetrahidro-5H-pirazolo[4,3-c]piridin-5-il]etil}-4-fluorobenzamid; N-{2-[2-(2-kloro-4-fluorofenil)-4-metil-3,6-diokso-1,2,3,6-tetrahidro-5H-pirazolo[4,3-c]piridin-5-il]etil}-4-fluorobenzamid; 2-[2-(2-kloro-4-fluorofenil)-4-metil-3,6-diokso-1,2,3,6-tetrahidro-5H-pirazolo[4,3-c]piridin-5-il]-N-(piridin-2-ilmetil)acetamid; N-(2-{2-[4-(benziloksi)fenil]-4-metil-3,6-diokso-1,2,3,6-tetrahidro-5H-pirazolo[4,3-c]piridin-5-il}etil)-4-fluorobenzamid; 2-((3-kloro-4-fluorofenil)-4-metil-5-[2-(morfolin-4-ilmetil)benzil]-1H-pirazolo[4,3-c]piridin-3,6(2H,5H)-dion; N-(3-{4-metil-5-[2-(morfolin-4-ilmetil)benzil]-3,6-diokso-1,3,5,6-tetrahidro-2H-pirazolo[4,3-c]piridin-2-il}fenil)acetamid; 2-((4-klorofenil)-4-metil-5-(3-fenoksibenzil)-1H-pirazolo[4,3-c]piridin-3,6(2H,5H)-dion; 2-[2-(3-kloro-4-fluorofenil)-4-metil-3,6-diokso-1,2,3,6-tetrahidro-5H-pirazolo[4,3-c]piridin-5-il]-N-(piridin-2-ilmetil)acetamid; 2-[4-butil-2-(3-kloro-4-fluorofenil)-3,6-diokso-1,2,3,6-tetrahidro-5H-pirazolo[4,3-c]piridin-5-il]-N-(piridin-2-ilmetil)acetamid; 2-[2-(2,3-diklorofenil)-4-metil-3,6-diokso-1,2,3,6-tetrahidro-5H-pirazolo[4,3-c]piridin-5-il]-N-(piridin-2-ilmetil)acetamid; 2-[2,4-bis(3-klorofenil)-3,6-diokso-1,2,3,6-tetrahidro-SH-pirazolo[4,3-c]piridin-5-il]-N-(piridin-2-ilmetil)acetamid; 4-((3-klorofenil)-5-(3-etoksipropil)-2-metil-1H-pirazolo[4,3-c]piridin-3,6(2H,5H)-dion; 2-[4-(3-klorofenil)-2-metil-3,6-diokso-1,2,3,6-tetrahidro-5H-pirazolo[4,3-c]piridin-5-il]-N-(piridin-2-ilmetil)acetamid; N-(3-{[4-(3-klorofenil)-2-metil-3,6-diokso-1,2,3,6-tetrahidro-5H-pirazolo[4,3-c]piridin-5-il]metil}fenil)acetamid; 2,4-bis(3-klorofenil)-5-(3-hidroksipropil)-1H-pirazolo[4,3-c]piridin-3,6(2H,5H)-dion; 2-((2-klorofenil)-4-metil-5-(2-morfolin-4-il-2-oksoetil)-1H-pirazolo[4,3-c]piridin-3,6(2H,5H)-dion; 4-((3-klorofenil)-2-metil-5-(2-morfolin-4-il-2-oksoetil)-1H-pirazolo[4,3-c]piridin-3,6(2H,5H)-dion; 4-((4-klorofenil)-2-metil-5-[4-(morfolin-4-ilmetil)benzil]-1H-pirazolo[4,3-c]piridin-3,6(2H,5H)-dion; N-{3-[4-(3-klorofenil)-5-(3-hidroksipropil)-3,6-diokso-1,3,5,6-tetrahidro-2H-pirazolo[4,3-c]piridin-2-il]fenil}acetamid; 4-((3-klorofenil)-2-metil-5-[3-(morfolin-4-ilmetil)benzil]-1H-pirazolo[4,3-c]piridin-3,6(2H,5H)-dion; 2-[4-(4-klorofenil)-2-metil-3,6-diokso-1,2,3,6-tetrahidro-5H-pirazolo[4,3-c]piridin-5-il]-N-(piridin-2-ilmetil)acetamid; 4-((3-klorofenil)-2-metil-5-[2-(morfolin-4-ilmetil)benzil]-1H-pirazolo[4,3-c]piridin-3,6(2H,5H)-dion; 4-((3-klorofenil)-2-metil-5-[4-(morfolin-4-ilmetil)benzil]-1H-pirazolo[4,3-c]piridin-3,6(2H,5H)-dion; 4-((3-klorofenil)-2-metil-5-[2-(4-metilpiperazin-1-il)-2-oksoetil]-1H-pirazolo[4,3-c]piridin-3,6(2H,5H)-dion; 2-((2-klorofenil)-4-metil-5-[2-(4-metilpiperazin-1-il)-2-oksoetil]-1H-pirazolo[4,3-c]piridin-3,6(2H,5H)-dion; 4-((4-klorofenil)-5-(3-etoksipropil)-2-metil-1H-pirazolo[4,3-c]piridin-3,6(2H,5H)-dion; 4-((4-klorofenil)-2-metil-5-[2-(morfolin-4-ilmetil)benzil]-1H-pirazolo[4,3-c]piridin-3,6(2H,5H)-dion; N-(3-{[4-(4-klorofenil)-2-metil-3,6-diokso-1,2,3,6-tetrahidro-5H-pirazolo[4,3-c]piridin-5-il]metil}fenil)acetamid; 4-((4-klorofenil)-2-metil-5-[3-(morfolin-4-ilmetil)benzil]-1H-pirazolo[4,3-c]piridin-3,6(2H,5H)-dion; 4-((4-klorofenil)-2-metil-5-[(6-morfolin-4-ilpiridin-2-il)metil]-1H-pirazolo[4,3-c]piridin-3,6(2H,5H)-dion; N-{2-[4-(4-klorofenil)-2-metil-3,6-diokso-1,2,3,6-tetrahidro-5H-pirazolo[4,3-c]piridin-5-il]etil}acetamid; 4-((4-klorofenil)-5-[3-(dimetilamino)benzil]-2-metil-1H-pirazolo[4,3-c]piridin-3,6(2H,5H)-dion; 4-((4-klorofenil)-2-metil-5-[(6-pirolidin-1-ilpiridin-2-il)metil]-1H-pirazolo[4,3-c]piridin-3,6(2H,5H)-dion; 2-((2-klorofenil)-4-(4-klorofenil)-5-(3-etoksipropil)-1H-pirazolo[4,3-c]piridin-3,6(2H,5H)-dion; 2-((2-klorofenil)-4-(4-klorofenil)-5-metil-1H-pirazolo[4,3-c]piridin-3,6(2H,5H)-dion; 2-((2-klorofenil)-4-(2-fluorofenil)-5-metil-1H-pirazolo[4,3-c]piridin-3,6(2H,5H)-dion; 2-((2-klorofenil)-4-(4-klorofenil)-5-[3-(dimetilamino)propil]-1H-pirazolo[4,3-c]piridin-3,6(2H,5H)-dion; 2-((2-klorofenil)-4-[3-(dimetilamino)fenil]-5-metil-1H-pirazolo[4,3-c]piridin-3,6(2H,5H)-dion; 2-((2-klorofenil)-5-metil-4-(3-morfolin-4-ilfenil)-1H-pirazolo[4,3-c]piridin-3,6(2H,5H)-dion; 2-((2-klorofenil)-4-[1-(3,4-difluorofenoksi)etil]-5-metil-1H-pirazolo[4,3-c]piridin-3,6(2H,5H)-dion; 4-[l-(benziloksi)etil]-2-(2-klorofenil)-5-metil-1H-pirazolo[4,3-c]piridin-3,6(2H,5H)-dion; i 4-[3-(dimetilamino)fenil]-2-(2-metoksifenil)-5-metil-1H-pirazolo[4,3-c]piridin-3,6(2H,5H)-dion.
13. Farmaceutski sastav koji sadrži najmanje jedan derivat prema bilo kojem od patentnih zahtjeva od 1 do 12 i njegov farmaceutski prihvatljiv nosač, razrjeđivač ili ekscipijens.
14. Derivat prema bilo kojem od patentnih zahtjeva od 1 do 12, naznačen time da je upotrebu kao lijek.
15. Derivat pirazolo piridina prema bilo kojem od patentnih zahtjeva od 1 do 12, naznačen time da je za liječenje bolesti ili stanja odabranih iz grupe koju čine kardiovaskularni poremećaji, respiratorni poremećaji, poremećaji metabolizma, kožni poremećaji, poremećaji kostiju, neuroinflamatorni i/ili neurodegenerativni poremećaji, bolesti bubrega, poremećaji reprodukcije, bolesti koje pogađaju oko i/ili leću oka i/ili stanja koja pogađaju unutarnje uho, upalni poremećaji, bolesti jetre, bol, tumori, alergijski poremećaji, traume, sepse, hemoragijski i anafilaktički šok, bolesti ili poremećaji gastrointestinalnog sistema, angiogeneza, stanja koja nastaju uslijed angiogeneze, kao i drugih bolesti i/ili poremećaja koja su povezana s nikotinamid adenin dinukleotid fosfat oksidazom (NADPH oksidaze).
16. Postupak za dobivanje spoja opće formule (I) koji sadrži korak ciklizacije spoja opće formule (VIII) u prisustvu baze: [image] naznačen time da je R18 C1-C6 alkil grupa poput metil, etil, propil, izopropil ili butil grupe; a G1 je H; dok su G2, G3, G4 i G5 kao što je to definirano u bilo kojem od prethodnih patentnih zahtjeva.
HRP20150082AT 2008-09-23 2015-01-22 Derivati pirazolo piridina kao inhibitori nadph oksidaze HRP20150082T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08164857A EP2166010A1 (en) 2008-09-23 2008-09-23 Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
PCT/IB2009/054156 WO2010035221A1 (en) 2008-09-23 2009-09-22 Pyrazolo pyridine derivatives as nadph oxidase inhibitors
EP09787271.7A EP2344492B1 (en) 2008-09-23 2009-09-22 Pyrazolo pyridine derivatives as nadph oxidase inhibitors

Publications (1)

Publication Number Publication Date
HRP20150082T1 true HRP20150082T1 (hr) 2015-04-10

Family

ID=40328866

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20150082AT HRP20150082T1 (hr) 2008-09-23 2015-01-22 Derivati pirazolo piridina kao inhibitori nadph oksidaze

Country Status (22)

Country Link
US (3) US9096588B2 (hr)
EP (3) EP2166010A1 (hr)
JP (2) JP5700837B2 (hr)
KR (3) KR101789479B1 (hr)
CN (1) CN102159573B (hr)
AU (1) AU2009298008B2 (hr)
BR (1) BRPI0919330A2 (hr)
CA (1) CA2737550C (hr)
CY (1) CY1115952T1 (hr)
DK (2) DK2344492T3 (hr)
ES (2) ES2673405T3 (hr)
HK (2) HK1159107A1 (hr)
HR (1) HRP20150082T1 (hr)
IL (1) IL211892A0 (hr)
PL (2) PL2344492T3 (hr)
PT (2) PT2860179T (hr)
RS (1) RS53781B1 (hr)
RU (1) RU2538041C2 (hr)
SI (1) SI2344492T1 (hr)
SM (1) SMT201500070B (hr)
TR (1) TR201808380T4 (hr)
WO (1) WO2010035221A1 (hr)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2002835A1 (en) 2007-06-04 2008-12-17 GenKyo Tex Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
EP2000176A1 (en) * 2007-06-04 2008-12-10 GenKyo Tex Tetrahydroindole derivatives as NADPH Oxidase inhibitors
EP2166009A1 (en) * 2008-09-23 2010-03-24 Genkyo Tex Sa Pyrazolo pyridine derivatives as nadph oxidase inhibitors
EP2166010A1 (en) * 2008-09-23 2010-03-24 Genkyo Tex Sa Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
EP2165707A1 (en) 2008-09-23 2010-03-24 Genkyo Tex Sa Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
EP2166008A1 (en) * 2008-09-23 2010-03-24 Genkyo Tex Sa Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
EP2305679A1 (en) 2009-09-28 2011-04-06 GenKyoTex SA Pyrazoline dione derivatives as nadph oxidase inhibitors
EP2361911A1 (en) 2010-02-18 2011-08-31 GenKyoTex SA Pyrazolo piperidine derivatives as NADPH oxidase inhibitors
WO2012170752A1 (en) * 2011-06-10 2012-12-13 Glaxo Wellcome Manufacturing Pte Ltd Novel compounds
EP2591782A1 (en) * 2011-11-11 2013-05-15 Johann Wolfgang Goethe-Universität Nadph oxidase 4 inhibitors and use thereof
JP2015535225A (ja) 2012-10-24 2015-12-10 グルソックス・バイオテック・アーベー ニコチンアミドアデニンジヌクレオチドリン酸オキシダーゼに関連する状態を処置するためのトリアジン誘導体
EP2857399A1 (en) 2013-10-03 2015-04-08 GenKyoTex SA Compounds useful for the treatment of PDE5 inhibitor-poorly responsive erectile dysfunction
US10173988B2 (en) 2015-02-16 2019-01-08 Glucox Biotech Ab N2-(3,4-dimethylphenyl)-6-((4-(p-tolyl)piperazin-1-yl)methyl)-1,3,5-triazine-2,4-diamine
US10251870B2 (en) * 2015-03-06 2019-04-09 Stc.Unm Method for treating obesity, diabetes, cardiovascular and kidney diseases by regulating GPR30/GPER activity
EP3098220A1 (en) 2015-05-28 2016-11-30 GenKyoTex SA Process for the preparation of a nadph oxidase inhibitor and its polymorphs and uses thereof
WO2017196982A1 (en) * 2016-05-10 2017-11-16 Georgia State University Research Foundation, Inc. Bicyclic fused pyrazole derivatives for the treatment of rsv
WO2018049214A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
US20180072741A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyrimidine compounds and uses thereof
WO2018049191A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyridone derivatives as hpk1 modulators and uses thereof for the treatment of cancer
CN115819417A (zh) 2016-09-09 2023-03-21 因赛特公司 作为hpk1调节剂的吡唑并吡啶衍生物及其用于治疗癌症的用途
US20180228786A1 (en) 2017-02-15 2018-08-16 Incyte Corporation Pyrazolopyridine compounds and uses thereof
EA201992343A1 (ru) * 2017-05-04 2020-04-16 Гленмарк Фармасьютикалс С.А. Замещенные бициклические гетероциклические соединения в качестве ингибиторов надфн-оксидазы
CN109562120B (zh) * 2017-08-11 2021-03-19 邦泰生物工程(深圳)有限公司 一种含有nadh和nadph的组合物及其应用
US10722495B2 (en) 2017-09-08 2020-07-28 Incyte Corporation Cyanoindazole compounds and uses thereof
EP3479843A1 (en) * 2017-11-01 2019-05-08 GenKyoTex Suisse SA Use of nox inhibitors for treatment of cancer
CN111601643A (zh) * 2017-11-15 2020-08-28 范德比尔特大学 用于改善溶酶体功能和治疗神经退行性疾病的方法和组合物
PL3755703T3 (pl) 2018-02-20 2022-11-07 Incyte Corporation Pochodne n-(fenylo)-2-(fenylo)pirymidyno-4-karboksyamidu i związki pokrewne jako inhibitory hpk1 do leczenia nowotworu
WO2019164847A1 (en) 2018-02-20 2019-08-29 Incyte Corporation Indazole compounds and uses thereof
US10745388B2 (en) 2018-02-20 2020-08-18 Incyte Corporation Indazole compounds and uses thereof
US11299473B2 (en) 2018-04-13 2022-04-12 Incyte Corporation Benzimidazole and indole compounds and uses thereof
US10899755B2 (en) 2018-08-08 2021-01-26 Incyte Corporation Benzothiazole compounds and uses thereof
EP3856348B1 (en) 2018-09-25 2024-01-03 Incyte Corporation Pyrazolo[4,3-d]pyrimidine compounds as alk2 and/or fgfr modulators
AU2020326703A1 (en) 2019-08-06 2022-02-17 Incyte Corporation Solid forms of an HPK1 inhibitor
EP4205740A1 (en) * 2020-08-28 2023-07-05 Celros Biotech Novel thiohydantoin derivatives and uses thereof
WO2023018560A1 (en) * 2021-08-13 2023-02-16 Georgia State University Research Foundation, Inc. Bicyclic fused pyrazole derivatives for the treatment of respiratory infections including rsv
US11896719B2 (en) 2022-01-24 2024-02-13 Calliditas Therapeutics Ab Pharmaceutical compositions
WO2023217764A1 (en) 2022-05-09 2023-11-16 Calliditas Therapeutics Suisse Sa Nox inhibitors for use in the treatment of alport syndrome

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3391407A (en) 1966-08-15 1968-07-09 William A. Waters Helmet
US3931407A (en) 1973-03-01 1976-01-06 American Hoechst Corporation Method of treatment with and compositions containing condensed pyrroles bearing an N-phenyl substituent
DE3728278A1 (de) * 1986-12-17 1988-06-23 Bayer Ag Herbizide und fungizide mittel auf basis von substituierten pyrazolin-5-on derivaten
DE19518082A1 (de) * 1995-05-17 1996-11-21 Merck Patent Gmbh 4(-Arylaminomethylen)-2,4-dihydropyrazol-3-one
US5763496A (en) 1995-11-27 1998-06-09 The Research Foundation Of State University Of New York Prevention of atherosclerosis using NADPH oxidase inhibitors
TW432073B (en) 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
AU6320998A (en) 1997-02-21 1998-09-09 Bristol-Myers Squibb Company Benzoic acid derivatives and related compounds as antiarrhythmic agents
IL144468A0 (en) 2000-07-27 2002-05-23 Pfizer Prod Inc Use of growth hormone secretagogues for improvement of functional health status
WO2002088122A1 (fr) 2001-04-26 2002-11-07 Ajinomoto Co., Inc. Composes heterocycliques
EP1291017A3 (en) 2001-09-10 2003-07-02 Warner-Lambert Company Use of statins to inhibit formation of osteoclasts
CA2483306A1 (en) * 2002-04-23 2003-11-06 Shionogi & Co., Ltd. Pyrazolo[1,5-a]pyrimidine derivative and nad(p)h oxidase inhibitor containing the same
US7179808B2 (en) 2002-07-03 2007-02-20 Janssen Pharmaceutica N.V. Substituted heteroaryl and heterocyclic compounds useful in treating inflammatory disorders
JP2006520326A (ja) 2003-02-28 2006-09-07 ハワード フローリー インスティチュート オブ エクスペリメンタル フィジオロジー アンド メディシン 治療薬
US20070082910A1 (en) 2003-04-08 2007-04-12 Mitsubishi Pharma Corporation Specific nad(p)h oxidase inhibitor
WO2005080378A1 (ja) 2004-02-24 2005-09-01 Mitsubishi Pharma Corporation 縮合ピリダジン誘導体
CA2582674A1 (en) 2004-10-04 2006-04-20 Myriad Genetics, Inc. Compounds for alzheimer's disease
FR2882654B1 (fr) 2005-03-01 2007-04-27 Servier Lab Utilisation de derives de la diosmetine pour le traitement et la prevention des pathologies thrombotiques
US7759337B2 (en) 2005-03-03 2010-07-20 Amgen Inc. Phthalazine compounds and methods of use
US20070014739A1 (en) * 2005-07-14 2007-01-18 Eldridge Gary R Compositions and methods for controlling biofilms and bacterial infections
DE102005048897A1 (de) 2005-10-12 2007-04-19 Sanofi-Aventis Deutschland Gmbh Diacylindazol-derivate als Inhibitoren von Lipasen und Phospholipasen
AU2007234399A1 (en) 2006-04-04 2007-10-11 Myriad Genetics, Inc. Compounds for diseases and disorders
AU2007292302A1 (en) * 2006-09-05 2008-03-13 Bipar Sciences, Inc. Methods for designing PARP inhibitors and uses thereof
ES2608659T3 (es) * 2006-11-13 2017-04-12 Pcb Associates, Inc. Composición para inhibir la actividad de la NADPH oxidasa
EP2002835A1 (en) * 2007-06-04 2008-12-17 GenKyo Tex Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
EP2000176A1 (en) 2007-06-04 2008-12-10 GenKyo Tex Tetrahydroindole derivatives as NADPH Oxidase inhibitors
PE20091093A1 (es) 2007-12-03 2009-08-25 Takeda Pharmaceutical Compuesto heterociclico que contiene nitrogeno y su uso
US20090163452A1 (en) 2007-12-20 2009-06-25 Schwartz Janice B Compositions and methods for lowering serum cholesterol
FR2929276B1 (fr) 2008-04-01 2010-04-23 Servier Lab Nouveaux derives de diosmetine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP2166009A1 (en) 2008-09-23 2010-03-24 Genkyo Tex Sa Pyrazolo pyridine derivatives as nadph oxidase inhibitors
EP2166010A1 (en) * 2008-09-23 2010-03-24 Genkyo Tex Sa Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
EP2166008A1 (en) 2008-09-23 2010-03-24 Genkyo Tex Sa Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
EP2165707A1 (en) 2008-09-23 2010-03-24 Genkyo Tex Sa Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
WO2010059646A2 (en) * 2008-11-18 2010-05-27 Plextronics, Inc. Aminobenzene compositions and related devices and methods
AU2009316680B2 (en) * 2008-11-18 2016-03-24 Takeda Vaccines, Inc. RSV F VLPs and methods of manufacture and use thereof
BRPI0921509A2 (pt) * 2008-11-19 2016-03-08 Vertex Pharma inibidor triazolotiadiazol de proteína quinase c-met
EP2305679A1 (en) 2009-09-28 2011-04-06 GenKyoTex SA Pyrazoline dione derivatives as nadph oxidase inhibitors
CA2823974A1 (en) 2010-01-08 2011-07-14 Beth Israel Deaconess Medical Center Methods and compositions for the treatment of migraine headaches
EP2361911A1 (en) 2010-02-18 2011-08-31 GenKyoTex SA Pyrazolo piperidine derivatives as NADPH oxidase inhibitors
EP2361912A1 (en) 2010-02-18 2011-08-31 GenKyoTex SA Pyrazolo piperidine derivatives as NADPH oxidase inhibitors
CN102014373B (zh) 2010-11-22 2015-04-01 中兴通讯股份有限公司 一种激活配置的方法及装置
EP2591782A1 (en) 2011-11-11 2013-05-15 Johann Wolfgang Goethe-Universität Nadph oxidase 4 inhibitors and use thereof

Also Published As

Publication number Publication date
IL211892A0 (en) 2011-06-30
CN102159573B (zh) 2015-05-27
KR101789479B1 (ko) 2017-10-23
PL2860179T3 (pl) 2018-08-31
ES2673405T3 (es) 2018-06-21
EP2344492A1 (en) 2011-07-20
CN102159573A (zh) 2011-08-17
CA2737550C (en) 2020-04-21
EP2344492B1 (en) 2014-10-29
US20110269757A1 (en) 2011-11-03
ES2528096T3 (es) 2015-02-03
US9096588B2 (en) 2015-08-04
BRPI0919330A2 (pt) 2016-06-07
PT2344492E (pt) 2015-02-09
SI2344492T1 (sl) 2015-02-27
DK2860179T3 (en) 2018-06-25
EP2860179A1 (en) 2015-04-15
EP2166010A1 (en) 2010-03-24
EP2860179B1 (en) 2018-03-14
CY1115952T1 (el) 2017-01-25
PT2860179T (pt) 2018-05-08
AU2009298008A1 (en) 2010-04-01
HK1208452A1 (en) 2016-03-04
RU2011116230A (ru) 2012-10-27
US20180235976A1 (en) 2018-08-23
PL2344492T3 (pl) 2015-04-30
WO2010035221A1 (en) 2010-04-01
KR20110056387A (ko) 2011-05-27
JP2012502981A (ja) 2012-02-02
KR101763096B1 (ko) 2017-07-28
US20150290208A1 (en) 2015-10-15
US10772891B2 (en) 2020-09-15
CA2737550A1 (en) 2010-04-01
RU2538041C2 (ru) 2015-01-10
JP5932008B2 (ja) 2016-06-08
HK1159107A1 (en) 2012-07-27
US9974791B2 (en) 2018-05-22
JP2015078222A (ja) 2015-04-23
KR20160142419A (ko) 2016-12-12
RS53781B1 (en) 2015-06-30
TR201808380T4 (tr) 2018-07-23
DK2344492T3 (en) 2015-02-02
AU2009298008B2 (en) 2014-07-31
JP5700837B2 (ja) 2015-04-15
ES2673405T8 (es) 2023-03-15
KR20170026643A (ko) 2017-03-08
SMT201500070B (it) 2015-05-05

Similar Documents

Publication Publication Date Title
HRP20150082T1 (hr) Derivati pirazolo piridina kao inhibitori nadph oksidaze
HRP20130143T1 (hr) Derivati pirazolo piridina kao inhibitori nadph oksidaze
HRP20171638T1 (hr) Derivati pirazolin diona kao inhibitori nadph oksidaze
HRP20130865T1 (hr) Derivati pirazol piridina kao inhibitori nadph oksidaze
HRP20201641T1 (hr) Novi spojevi i njihove farmaceutske kompozicije za liječenje inflamatornih poremećaja
RU2018123779A (ru) Новые соединения
HRP20200781T1 (hr) DERIVATI PIRAZOLO[1,5-a]PIRAZIN-4-ILA KAO INHIBITORI JAK
HRP20191821T1 (hr) Antiproliferativni spojevi i načini njihove uporabe
RU2011116232A (ru) Пиразолопиридиновые производные как ингибиторы надфн-оксидазы
JP2016523911A5 (hr)
JP2012501312A5 (hr)
HRP20110834T1 (hr) Piridin metilen azolidinoni i njihova uporaba kao inhibitora fosfoinozitida
JP2012525431A5 (hr)
JP2012502981A5 (hr)
JP2009542721A5 (hr)
JP2013505930A5 (hr)
MY136516A (en) Heterocyclic compounds useful for the treatment of inflammatory and allergic disorders, process for their preparation and pharmaceutical compositions containing them
CA2512441A1 (en) Thienopyrimidinediones and their use in the modulation of autoimmune disease
RU2016122563A (ru) Тетрагидробензодиазепиноны
RU2006134021A (ru) Производные гетероарил-конденсированного пиразола
WO2000047558A1 (fr) Composes amide et leur utilisation medicinale
JP2019504901A5 (hr)
JP2007521287A5 (hr)
JP2006515604A5 (hr)
HRP20100401T1 (hr) DERIVATI PIRAZOLO/3,4-d/AZEPINA KAO HISTAMINSKI H3 ANTAGONISTI